GR3032326T3 - Ocular androgen therapy in sjögren's syndrome. - Google Patents

Ocular androgen therapy in sjögren's syndrome.

Info

Publication number
GR3032326T3
GR3032326T3 GR20000400024T GR20000400024T GR3032326T3 GR 3032326 T3 GR3032326 T3 GR 3032326T3 GR 20000400024 T GR20000400024 T GR 20000400024T GR 20000400024 T GR20000400024 T GR 20000400024T GR 3032326 T3 GR3032326 T3 GR 3032326T3
Authority
GR
Greece
Prior art keywords
syndrome
ocular
sjögren
androgen therapy
androgen
Prior art date
Application number
GR20000400024T
Other languages
English (en)
Inventor
David A Sullivan
Original Assignee
Schepens Eye Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schepens Eye Res Inst filed Critical Schepens Eye Res Inst
Publication of GR3032326T3 publication Critical patent/GR3032326T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Eye Examination Apparatus (AREA)
  • Steroid Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR20000400024T 1992-04-21 2000-01-07 Ocular androgen therapy in sjögren's syndrome. GR3032326T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87165792A 1992-04-21 1992-04-21
PCT/US1993/003801 WO1993020823A1 (en) 1992-04-21 1993-04-21 Ocular androgen therapy in sjögren's syndrome

Publications (1)

Publication Number Publication Date
GR3032326T3 true GR3032326T3 (en) 2000-04-27

Family

ID=25357867

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000400024T GR3032326T3 (en) 1992-04-21 2000-01-07 Ocular androgen therapy in sjögren's syndrome.

Country Status (11)

Country Link
US (1) US5620921C1 (el)
EP (1) EP0643581B1 (el)
JP (1) JPH07508716A (el)
AT (1) ATE185697T1 (el)
AU (1) AU674681B2 (el)
CA (1) CA2133966C (el)
DE (1) DE69326836T2 (el)
DK (1) DK0643581T3 (el)
ES (1) ES2139005T3 (el)
GR (1) GR3032326T3 (el)
WO (1) WO1993020823A1 (el)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
JPH08507884A (ja) * 1993-03-12 1996-08-20 アラーガン、インコーポレイテッド フェロモン添加剤を含有するアイケア用品およびその使用方法
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6462080B1 (en) 1998-12-24 2002-10-08 Alcon Manufacturing, Ltd. Prostaglandin E receptor agonists for treatment of dry eye
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
MXPA02004703A (es) 1999-11-09 2004-09-10 Alcon Inc Composiciones que contienen derivados de acido hidroxieicostetraenoico y metodos de uso para tratar trastornos de resequedad en los ojos.
MXPA02004701A (es) 1999-11-09 2004-09-10 Alcon Inc Sales de hidroxieicosatetraenoato, composiciones y metodos de uso para tratar trastornos de resequedad en los ojos.
US6255343B1 (en) 1999-11-09 2001-07-03 Alcon Universal Ltd. 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
US6458854B2 (en) 1999-11-09 2002-10-01 Alcon Universal Ltd. Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
US6353012B1 (en) 1999-11-09 2002-03-05 Alcon Universal Ltd. 15-Hydroxyeicosatetraenoic acid-related compounds and methods of use
PT1227809E (pt) 1999-11-09 2005-06-30 Alcon Inc Analogos do acido 15-hidroxieicosatetraenoico interrompidos por um heteroatomo e metodos de utilizacao
US6552084B2 (en) 1999-11-09 2003-04-22 Alcon Universal Ltd. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
US6353032B1 (en) 1999-11-09 2002-03-05 Alcon Universal Ltd. Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
CN1387435A (zh) 1999-11-09 2002-12-25 爱尔康公司 用于治疗干眼的脂毒素a4及其衍生物
US6803385B2 (en) 1999-11-09 2004-10-12 Alcon, Inc. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
TR200201251T2 (tr) 1999-11-09 2002-11-21 Alcon, Inc. Omega zinciri tadil edilmiş 15-hidroksieikosatetraenoik asit türevleri ve bunların göz kurumasının iyileştirilmesi için kullanım yöntemleri
WO2001034548A2 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. 3-heteroatom substituted and two carbon homologs of 15-hete and methods of use
DE60020591T2 (de) 1999-11-09 2005-11-10 Alcon Inc. Benzenoidderivate von 15-hydroxyeicosatetraesäure und verfahren zur verwendung zur behandlung des trockenen auges
WO2001034550A2 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
US6576663B2 (en) 1999-12-22 2003-06-10 Alcon, Inc. 6-Keto prostaglandin F1α and analogs for treating dry eye
PL361027A1 (en) 2000-07-14 2004-09-20 Allergan,Inc. Compositions containing therapeutically active components having enhanced solubility
DK1330246T3 (da) 2000-10-23 2005-08-08 Alcon Inc Anvendelse af hydroxyicosatetraensyrederivater ved intraokulær kirurgi
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
CA2447909C (en) 2001-05-21 2011-04-05 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
PT1393277E (pt) 2001-05-21 2006-09-29 Alcon Inc Utilizacao de inibidores de nf-kb para tratar disturbios de olho seco
PL367097A1 (en) * 2001-05-21 2005-02-21 Alcon, Inc. Method of treating dry eye disorders
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
WO2003030894A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye
MXPA04003299A (es) * 2001-10-11 2004-07-23 Alcon Inc Metodos para tratar la resequedad ocular mediante una combinacion de un esteroide antiinflamatorio y un secretagogo muc-1.
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
WO2004060274A2 (en) * 2002-12-20 2004-07-22 Alcon, Inc. Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
TWI335819B (en) * 2002-12-24 2011-01-11 Alcon Inc Use of oculosurface selective glucocorticoid in the treatment of dry eye
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
FR2877574A1 (fr) * 2004-11-08 2006-05-12 Marie Claude Benattar Utilisation d'acide hyaluronique, eventuellement en association avec au moins un androgene pour le traitement de troubles sexuels ou urinaires feminins par amplification du point g et compositions.
AU2006218655A1 (en) * 2005-03-02 2006-09-08 Nascent Pharmaceutical. Inc. Combinaion therapy for topical application in the treatment of dry eye syndrome
DE202006021081U1 (de) * 2005-07-12 2012-05-08 Dmi Biosciences, Inc. Produkte zur Behandlung von Krankheiten
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
RU2510274C2 (ru) * 2008-05-07 2014-03-27 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Терапевтическое восстановление и усиление увлажнения поверхности глаза
AU2010264524B2 (en) 2009-06-22 2015-03-19 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
CA2765883A1 (en) * 2009-06-22 2010-12-29 Dmi Acquisition Corp. Methods and products for treatment of diseases
BR112013019257B1 (pt) 2011-01-26 2019-09-03 Allergan Inc composição de androgênio para tratar uma condição oftálmica
AU2013361338A1 (en) 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
WO2014149998A1 (en) * 2013-03-15 2014-09-25 Lin, Qing Systemic administration of androgen in treating dry eye syndrome
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
MX2017012708A (es) * 2015-04-03 2018-01-09 Santen Pharmaceutical Co Ltd Agente terapeutico para ojo seco que comprende nandrolona o ester del mismo o metenolona o ester del mismo como un ingrediente activo.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4581226A (en) * 1983-04-07 1986-04-08 Dillon Richard S Method of treating sensitive animal tissue with a specially processed seawater solution
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
SE8305864D0 (sv) * 1983-10-25 1983-10-25 L E Medical Ogondroppar
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4812448A (en) * 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4863912A (en) * 1986-05-19 1989-09-05 New York Medical College Use of tetrahydrocortisol in glaucoma therapy
US4861763A (en) * 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US4866049A (en) * 1987-08-10 1989-09-12 Spectra Pharmaceutical Services, Inc. Ophthalmic compositionn and method of using same
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US4951683A (en) * 1989-01-19 1990-08-28 Davis Jeffrey P Device for detecting keratoconjunctivitis sicca

Also Published As

Publication number Publication date
US5620921A (en) 1997-04-15
EP0643581A4 (en) 1995-01-11
DE69326836T2 (de) 2000-02-24
AU674681B2 (en) 1997-01-09
CA2133966C (en) 1997-09-09
JPH07508716A (ja) 1995-09-28
AU4112193A (en) 1993-11-18
ATE185697T1 (de) 1999-11-15
WO1993020823A1 (en) 1993-10-28
ES2139005T3 (es) 2000-02-01
EP0643581A1 (en) 1995-03-22
US5620921C1 (en) 2001-01-09
DK0643581T3 (da) 2000-04-25
CA2133966A1 (en) 1993-10-28
DE69326836D1 (de) 1999-11-25
EP0643581B1 (en) 1999-10-20

Similar Documents

Publication Publication Date Title
US5620921C1 (en) Ocular androgen therapy in sjogren's syndrome
EP0233758A3 (en) Lotion and cream applicator, and body roller and massager
EP0253094A3 (en) Use of prostaglandin d2-active substances in the treatment of ocular hypertension and glaucoma
EP0142426A3 (en) Ophthalmic formulation containing norfloxacin and related antibiotics
TW250435B (el)
NO952469D0 (no) Terapautisk kombinasjon som inneholder interferon
AU7085996A (en) Therapeutic preparation for the transdermal application of active substances through the skin
CA2151724A1 (en) Antipyretic and Analgesic Methods and Compositions Containing Optically Pure R-Ketorolac
HK26294A (en) Stabilization of the preservative thiomersal in ophthalmic pharmaceutical compositions
IE791235L (en) Acyl-derivatives of carnitine.
IE40860L (en) N- heterocyclylalkylbenzamides
IT1177863B (it) Una miscela gangliosidica come agente terapeutico capare di eliminare il dolore nele neuropatie periferiche
USD268524S (en) Acupressure instrument for applying rolling pressure to the human body
ZA934021B (en) Treatment of bovine mastitis
ATE180667T1 (de) Verwendung grenzwertig wirksamer arzneiformen mit betablockern
汪承柏 et al. THE JAUNDICE-SUPPRESSING EFFECT OF BLOOD-COOLING, CIRCULATION-INVIGORATING, VISCERA-DREDGING AND CHOLAGOGIC CHINESE HERBS IN THE TREATMENT OF HEPATITIS
AU7719591A (en) Therapeutic agent
葛通远 et al. AN APPROACH TO THE MECHANISMS OF LASER ACUPUNCTURE IN TREATMENT OF EXOPHTHALMIC HYPERTHYROIDISM
ES8602799A1 (es) Un procedimiento para preparar 6-metilsulfoxido-espiro-(croman-4,4'-imidazolidin)-2',5'-diona
ATE72115T1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
NL7513892A (en) Ascorbic acid medicaments for external use - as nasal decongestants and to promote resistance to infection
WO1997004790A3 (de) Arzneimittel zur behandlung von ulcera welches magnesiumionen als wirksubstanz umfasst
USD286415S (en) Walking stilt
冯如珍 RELIEF OF OESOPHAGEAL CARCINOMATOUS OBSTRUCTION BY ACUPUNCTURE
郑惠田 et al. TREATMENT OF DIABETIC CYSTOPATHY BY ACUPUNCTURE AND MOXIBUSTION